Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Completed 21Recruiting 10Not yet recruiting 4Active not recruiting 4Unknown 3Terminated 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 3Gastrointestinal 1

Conditions

Colorectal Neoplasms 17Stomach Neoplasms 14Rectal Neoplasms 10Pancreatic Neoplasms 7Colonic Neoplasms 6Biliary Tract Neoplasms 5Adenocarcinoma 4HER2-positive Gastric Cancer 3Esophageal Neoplasms 3Cholangiocarcinoma 3Ovarian Neoplasms 2Neoplasms 2Lymphoma, Extranodal NK-T-Cell 2Locally Advanced Gastric Cancer 2Cirrhosis, Familial, with Pulmonary Hypertension 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Neoplasm, Residual 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1Locally Advanced Rectal Cancer 1Locally Advanced Low Rectal Adenocarcinoma 1

Interventions

Oxaliplatin 4Capecitabine 3Radiotherapy 2Docetaxel 2Androgen Antagonists 2tislelizumab 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1enzalutamide 1cemiplimab 1Surgical Procedures, Operative 1Radiotherapy, Image-Guided 1Poly(ADP-ribose) Polymerase Inhibitors 1PF06821497 1Negative-Pressure Wound Therapy 1Leuprolide 1Leucovorin 1Injections 1Fluorouracil 1Drug Therapy 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma × Oxaliplatin × Clear all
NCT07281768 2026-05-06

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Not yet recruiting
66 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Rectal Neoplasms, Colorectal Neoplasms

NCT07385703 2026-02-04

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Not yet recruiting
752 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT07118800 2025-08-12

NACRE-2

UNICANCER

Phase 3 Not yet recruiting
160 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡